兰索拉唑

lán suǒ lā zuò
  • Lansoprazole
兰索拉唑兰索拉唑
  1. 反相HPLC法测定兰索拉唑原料及片剂的含量

    Determination of Lansoprazole in the Raw Material and Its Tablets by RP HPLC

  2. RP-HPLC法测定人血浆中兰索拉唑肠溶片血药浓度

    RP-HPLC determination of lansoprazole enterosoluble tablets in human plasma

  3. HPLC测定注射用兰索拉唑中兰索拉唑的含量和有关物质

    Determination of Lansoprazole and Its Related Substance in Lansoprazole for Injection by HPLC

  4. RP-HPLC法测定兰索拉唑口崩片的含量

    Determination of Lansoprazole Orally Disintegrating Tablets by RP-HPLC

  5. 目的:探讨抑酸药兰索拉唑对幽门螺杆菌HelicobacterPylori(简称H.pylori)在胃内分布的影响。

    Objective : To investigate the effect of the acid inhibitor-Lansoprazole on the distribution of Helicobacter pylori ( H.pylori ) in stomach .

  6. 兰索拉唑每日15mg与每日30mg治疗消化性溃疡的比较

    Lansoprazole 15 mg vs 30 mg daily in treatment of peptic ulcer

  7. 目的:观察兰索拉唑、阿奇霉素和甲硝唑短程低剂量三联疗法根除幽门螺杆菌(Hp)的临床疗效和治疗费用。

    AIM : To observe the effect and therapy cost of short-term low-dose triple therapy with azithromycin , metronidazole and lansoprazole for the eradication of Helicobacter pylori ( Hp ) .

  8. 法莫替丁组和兰索拉唑组Hp根除率分别为88.1%和90.0%;十二指肠溃疡和/或胃溃疡的愈合率分别为90.5%和92.5%。

    The rate of Hp eradication for Famotidine and Lansoprazole group were 88.1 and 90.0 percent respectively , and the healing rate of peptic ulcer for them were 90.5 and 92.5 percent respectively .

  9. 兰索拉唑15mg与30mg治疗十二指肠溃疡效果及其安全性比较

    Comparison of lansoprazole 15 mg and 30 mg in the treatment of duodenal ulcer disease in China

  10. 目的:探索兰索拉唑15mg/d和30mg/d治疗消化性溃疡的比较。

    AIM : To compare lansoprazole 15 mg and 30 mg daily in the treatment of peptic ulcer .

  11. 一项涉及近300万人的数据的分析显示,目前广泛用于预防胃反流的药物——质子泵抑制剂(protonpumpinhibitors,P.P.I.,如奥美拉唑和兰索拉唑等)可能会增加心肌梗死的风险。

    The widely used drugs known as proton pump inhibitors , or P.P.I. 's - gastric reflux preventives like Prilosec and Prevacid - may increase the risk for heart attack , according to analysis of data involving almost three million people .

  12. 目的:了解含有质子泵抑制剂(PPI)兰索拉唑的短期三联疗法对幽门螺杆菌(HP)根治的效果、不良反应及溃疡愈合和复发情况。

    AIM : To evaluate the effect of short term triple therapy including proton pump inhibitor ( PPI ) for H. pylori ( HP ) eradication treatment . METHODS : Clo-tests for HP detec-tion were applied in 152 patients with peptic ulcer disease .

  13. 结果:与模型损伤组相比,兰索拉唑组大鼠UI明显降低(P<0.01),溃疡坏死组织和中性粒细胞浸润程度明显减轻(P<0.01)。

    Results : Ulcer index of the lansoprazole group was much lower than that of the control group ( P < 0.01 ), and the degree of necrotic tissues and neutrophils submersion the lansoprazole group was much milder than that of the control group ( P < 0.01 ) .

  14. 背景:研究表明细胞色素P4502C19(CYP2C19)参与质子泵抑制剂(PPIs)的代谢,是奥美拉唑、兰索拉唑和泮托拉唑的主要代谢途径。

    Background : Many studies have indicated that cytochrome P4502C19 ( CYP2C19 ) involved in the metabolism of proton pump inhibitors ( PPIs ), and it is the main metabolic pathway of omeprazole , lansoprazole and pantoprazole .

  15. 背景:兰索拉唑(Lansoprazole,LPZ)是第一代安全、高效的质子泵抑制剂。临床上已广泛用于消化系统疾病的治疗。

    Background : Lansoprazole is a safe and efficient proton pump inhibitor ( H + - K + - ATP enzyme ) of the first generation , which has been widely used in the treatment of peptic diseases .

  16. 目的制备性质稳定的兰索拉唑肠溶片。

    OBJECTIVE To design a more stable formulation of Lansoprazole enteric-tablets .

  17. 非心源性胸痛患者的食管动力异常及兰索拉唑治疗

    Esophageal motility investigation and lansoprazole empiric therapy for noncardiac chest pain

  18. 注射用兰索拉唑制备、质量控制及稳定性考察

    Preparation , quality control and stability study for lansoprazole for injection

  19. 注射用兰索拉唑有关物质测定方法的改进

    Improvement in determination method of related substances in Lansoprazole for Injection

  20. 兰索拉唑口服治疗消化性溃疡急性大出血

    Lansoprazole orally in treating peptic ulcer with acute massive bleeding

  21. 兰索拉唑可提高铋剂三联根除幽门螺杆菌的疗效

    Lansoprazole enhances efficacy of Bismuth-triple therapy in eradicating Helicobacter Pylori

  22. 兰索拉唑对预防脑梗死并发消化道出血的临床观察

    Clinical Observation on Lansoprazole to Prevention Cerebral Infarction Combined with Digestive Hemorrhage

  23. 兰索拉唑治疗十二指肠溃疡

    Study on the efficacy of lansoprazole in treatment of duodenal ulcer disease

  24. 兰索拉唑片相对生物利用度与生物等效性研究

    Study on the Relative Bioavailability and Bioequivalence of Lansoprazole Table

  25. 兰索拉唑治疗十二肠溃疡232例近期疗效观察

    Therapeutic Effect of Lansoprazole on Duodenal Ulcer : Clinical Analysis of 232 Cases

  26. 目的改进兰索拉唑的合成工艺。

    Aim To improve synthetic process of lansoprazole .

  27. 目的建立测定人血浆中兰索拉唑浓度的高效液相色谱方法。

    Objective An HPLC method was established for determination of lansoprazole in human serum .

  28. 兰索拉唑抗实验性胃溃疡作用的研究

    Effect of lansoprazole on gastric ulceration in rats

  29. 新一代质子泵抑制剂兰索拉唑的药理与临床应用新进展

    Progress of pharmacological and clinical application of lansoprazole , a new proton pump inhibitor

  30. 兰索拉唑肠溶片的研究奥美拉唑肠溶片生物利用度测定

    Studies on Bioavailability Assessment of Omeprazole Enteric-coated Tablets